Psoriasis: Risankizumab ‘safe and efficacious’ over two years
And patients who respond well to the therapy but then withdraw have some residual benefit
Many patients with chronic plaque psoriasis who have responded well to risankizumab are likely to maintain a good response over two years of continuous therapy, according to clinical trial results.
In the double-blinded IMMhance trial, patients with stable moderate to severe disease who had received three doses of 150mg risankizumab (at 0, 4 and 16 weeks) and had achieved a static Physicians Global Assessment score of zero or one (sPGA 0/1), were re-randomised either to remain on the therapy every 12 weeks, or to receive placebo injections.
